JP2021534208A - 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 - Google Patents

高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 Download PDF

Info

Publication number
JP2021534208A
JP2021534208A JP2021510013A JP2021510013A JP2021534208A JP 2021534208 A JP2021534208 A JP 2021534208A JP 2021510013 A JP2021510013 A JP 2021510013A JP 2021510013 A JP2021510013 A JP 2021510013A JP 2021534208 A JP2021534208 A JP 2021534208A
Authority
JP
Japan
Prior art keywords
subject
diabetes
fixed dose
ezetimibe
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021510013A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534208A5 (https=
Inventor
ラルワニ，ナレンドラ，ダンラージュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69591419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2021534208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of JP2021534208A publication Critical patent/JP2021534208A/ja
Publication of JP2021534208A5 publication Critical patent/JP2021534208A5/ja
Priority to JP2024032974A priority Critical patent/JP2024081650A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021510013A 2018-08-24 2019-08-26 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法 Pending JP2021534208A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024032974A JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722766P 2018-08-24 2018-08-24
US62/722,766 2018-08-24
US201862751404P 2018-10-26 2018-10-26
US62/751,404 2018-10-26
PCT/US2019/048184 WO2020041799A1 (en) 2018-08-24 2019-08-26 Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024032974A Division JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Publications (2)

Publication Number Publication Date
JP2021534208A true JP2021534208A (ja) 2021-12-09
JP2021534208A5 JP2021534208A5 (https=) 2022-11-09

Family

ID=69591419

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510013A Pending JP2021534208A (ja) 2018-08-24 2019-08-26 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
JP2024032974A Pending JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024032974A Pending JP2024081650A (ja) 2018-08-24 2024-03-05 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法

Country Status (15)

Country Link
US (1) US20210322376A1 (https=)
EP (1) EP3841105A4 (https=)
JP (2) JP2021534208A (https=)
KR (1) KR20210079275A (https=)
CN (1) CN113166195A (https=)
AU (1) AU2019325705A1 (https=)
BR (1) BR112021003265A2 (https=)
CA (1) CA3110346A1 (https=)
CL (1) CL2021000444A1 (https=)
CO (1) CO2021003726A2 (https=)
IL (1) IL281016A (https=)
MX (1) MX2021002090A (https=)
PH (1) PH12021550656A1 (https=)
SG (1) SG11202101717WA (https=)
WO (1) WO2020041799A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008000684A1 (es) * 2007-03-09 2008-08-01 Indigene Pharmaceuticals Inc Composicion farmaceutica que comprende metformina r-(+) lipoato y un inhibidor de reductasa hmg-coa; formulacion de dosis unitaria; y uso en el tratamiento de una complicacion diabetica.
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
CN103239449A (zh) * 2012-12-26 2013-08-14 辽宁亿灵科创生物医药科技有限公司 一种依折麦布、辛伐他汀和烟酸的复方制剂及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2018148417A1 (en) * 2017-02-08 2018-08-16 Esperion Therapeutics, Inc. Triplet combination formulations and methods of treating or reducing the risk of cardiovascular disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients withhyperchol", ATHEROSCLEROSIS, vol. 277, JPN6023036379, 12 June 2018 (2018-06-12), pages 195 - 203, ISSN: 0005316442 *

Also Published As

Publication number Publication date
SG11202101717WA (en) 2021-03-30
CN113166195A (zh) 2021-07-23
CO2021003726A2 (es) 2021-07-30
CL2021000444A1 (es) 2021-07-02
MX2021002090A (es) 2021-04-28
WO2020041799A1 (en) 2020-02-27
KR20210079275A (ko) 2021-06-29
BR112021003265A2 (pt) 2021-05-18
PH12021550656A1 (en) 2022-03-14
EP3841105A1 (en) 2021-06-30
JP2024081650A (ja) 2024-06-18
US20210322376A1 (en) 2021-10-21
IL281016A (en) 2021-04-29
EP3841105A4 (en) 2022-05-04
AU2019325705A1 (en) 2021-03-18
CA3110346A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
US10016426B2 (en) Pharmaceutical compositions for substituted quinazolinones
CA3018132C (en) Use of elafibranor in the treatment of a cholestatic disease
US20250064767A1 (en) Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease
JP6940411B2 (ja) Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
EA028378B1 (ru) Дейтерированные производные ивакафтора
KR20210151816A (ko) 칸나비노이드 산 에스테르 조성물 및 이의 용도
JP2024081650A (ja) 高コレステロール関連疾患について処置されている患者において糖尿病のリスクを低減させる方法
WO2019209738A1 (en) Use of neutrophil elastase inhibitors in liver disease
JP2022541503A (ja) Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置
TW202114671A (zh) 包含fxr促效劑之治療
JP2021535136A (ja) 心血管疾患及び関連する状態を有する患者を処置するための併用薬製剤
HK40111798A (zh) 大麻素酸酯组合物及其用途
WO2025036347A1 (zh) Pcsk9抑制剂用于治疗或预防胆固醇相关疾病的方法
TW202604485A (zh) 患有肝損傷患者肝疾病之治療
HK40063789B (zh) 大麻素酸酯组合物及其用途

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221031

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240507